Rosiglitazone is part of a group of diabetes medications called thiazolidinediones (or sometimes called "glitazones"). The drug helps to improve insulin sensitivity, meaning that it helps your body to use its natural insulin better. This helps to lower blood sugar and keep it under better control.
Effects of Rosiglitazone
There have been several studies looking at the effects of rosiglitazone for type 2 diabetes.
Hemoglobin A1c (HbA1c) is a test used to measure long-term blood sugar control. For people without diabetes, HbA1c results are usually less than 6 percent, while people with diabetes usually have higher results. In one study, people taking rosiglitazone lowered their HbA1c by up to 0.7 percent (on average), while the HbA1c in people not taking it increased by 0.8 percent.
Studies have shown that the higher the HbA1c, the greater the chance for developing long-term problems related to diabetes. This includes problems such as heart disease, diabetic retinopathy, diabetic neuropathy, and diabetic nephropathy. By getting blood sugar levels under control with rosiglitazone, it may be possible to decrease the chances for developing these diabetes complications.
Fasting Blood Sugar
Fasting blood sugar is another way to study the effects of a diabetes medication. In studies, people taking rosiglitazone decreased their fasting blood sugar levels by 25 to 55 mg/dL, while people not taking it increased their fasting blood sugar.
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Avandia [package insert]. Research Triangle Park, NC: GlaxoSmithKline;2011 February.
Food and Drug Administration, Center for Drug Evaluation and Research. FDA Drug Safety Communication: FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines (November 25, 2013). FDA Web site. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm376389.htm. Accessed December 20, 2013.
Food and Drug Administration, Center for Drug Evaluation and Research. Avandia (rosiglitazone): REMS - risk of cardiovascular events (9/23/2010). FDA Web site. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm226994.htm. Accessed October 1, 2010.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed April 10, 2012.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click